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Klimach et al.1 make a strong case for the use of buccal
midazolam (BM) in the community. In our district general hospital
at Queen’s Hospital, Burton on Trent we introduced BM in 2006 for
the management of prolonged seizures. Parents and carers are
advised and trained to administer the drug for out of hospital use.
BM is prescribed as a take home medication with an information
leaﬂet to assist parents/carers. We carried out a survey recently to
assess the awareness and estimate experience in its use as well as
satisfaction of healthcare professionals and parents with BM.
Of 134 questionnaires returned and analysed—53 parents, 81
health care professionals took part. Only 34% of parents or carers
were aware of or educated to use BM. But 78% of parents familiar
with BMhad administered it. All the users reported a high degree of
satisfaction in administration aswell as effectiveness of BM. Seizure
control was achieved in 88% of cases after the ﬁrst dose with no
severe adverse effects. Our study highlights the lack of awareness of
BM amongst parents and carers (34%). Despite the reduced
awareness, majority of parents who were made aware used the
drug and were highly satisﬁed with its administration and efﬁcacy.
Randomized multicentre controlled trials comparing BM with
rectal diazepam have established its safety, efﬁcacy as well as
superiority or comparable effectiveness.2,3 Klimach et al.1 with
their manuscript have now closed the void of lack of data in the
community. Despite these studies the awareness amongst parents
and carers is not satisfactory resulting in reduced use and minimal
beneﬁt to patients. From our experience awareness needs to be
augmented amongst parents and carers and paramedical person-
nel. This will aid in reducing the duration of seizure and make
management easier, both in and out of hospital setting. Regular
educational sessions and incorporating the use of BM into local,
regional and national guidelines will ensure its effective imple-
mentation in practice.1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
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